{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-016317","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.245025+00:00","generated_at":"2026-05-30T00:20:46.402830+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission","bullets":["Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).","Completed pre-BLA meeting with FDA; full alignment on BLA content for PRGN-2012 in RRP; rolling submission planned Q4 2024.","Commercial and manufacturing readiness underway for potential 2025 launch of PRGN-2012.","Confirmatory trial for PRGN-2012 initiated; end of Phase 1b meeting for PRGN-3006 in AML expected early 2025.","August 2024 equity offering raised net $30.9M; workforce reduced by over 20%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-016317","json":"https://secwatch.observer/filing/0000950103-24-016317.json","markdown":"https://secwatch.observer/filing/0000950103-24-016317.md","text":"https://secwatch.observer/filing/0000950103-24-016317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324016317/0000950103-24-016317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324016317/dp220702_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:20:46.402830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}